<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05097898</url>
  </required_header>
  <id_info>
    <org_study_id>2020PI145-3</org_study_id>
    <nct_id>NCT05097898</nct_id>
  </id_info>
  <brief_title>Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation</brief_title>
  <acronym>CHF-COV-P</acronym>
  <official_title>Évaluation de la Congestion en Hospitalisation de Jour Pour un Bilan d'Insuffisance Cardiaque Chronique à Fraction d'éjection préservée. CHF-COV Preserved (Chronic Heart Failure With Preserved Ejection Fraction - COngestion eValuation)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Central Hospital, Nancy, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Central Hospital, Nancy, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Heart failure (HF) is a significant cause of death and the leading cause of hospitalization&#xD;
      in patients over 65 years of age. Congestion is the main source of symptoms and the leading&#xD;
      cause of hospitalization for HF. Furthermore, congestive signs identified in asymptomatic&#xD;
      patients are associated with the risk of developing symptomatic HF. The literature supports a&#xD;
      multi-modality / integrative evaluation of congestion, combining clinical examination,&#xD;
      laboratory results and ultrasound evaluation.&#xD;
&#xD;
      The main objective of the CHF-COV Preserved study is to identify congestion markers&#xD;
      (clinical, biological and ultrasound) in day hospitalization for the monitoring of chronic HF&#xD;
      with preserved left ventricular ejection fraction that are associated with the risk of&#xD;
      all-cause death, hospitalization for acute HF or IV diuretics injection in a day hospital.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 10, 2021</start_date>
  <completion_date type="Anticipated">June 10, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 10, 2028</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 2 and 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 3)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of day-hospital or in-home IV diuretics injection for acute HF</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : rate of death from all causes, hospitalisation for acute heart failure or day-hospital IV diuretics injection for acute HF during 24 months following day hospitalization (with outcome 1 and 2)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of B-lines measured in lung echography</measure>
    <time_frame>At baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 6)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after day hospitalization (with outcome 9)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of day-hospital or in-home IV diuretics injection for acute HF</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint: Rate of hospitalisation for acute heart failure or day-hospital/in-home IV diuretics injection for acute HF 24 months after day hospitalization (with outcome 8)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for cardiovascular reason</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of death from all causes</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 12)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalisation for acute heart failure</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>composite endpoint : Rate of death from all causes or hospitalisation for acute heart failure 24 months after day hospitalization (with outcome 11)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of cardiovascular death</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>NYHA (New York Heart Association) class measured</measure>
    <time_frame>3, 12 and 24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Natriuretic peptides</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>BNP or Nt-Pro BNP</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal function</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>Assessed by glomerular filtration rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma volume</measure>
    <time_frame>24 months after day hospitalization</time_frame>
    <description>Calculated from haemoglobin and haematocrit value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of bilirubin</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ASAT</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of ALAT</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of V factor</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood potassium concentration</measure>
    <time_frame>24 months after day hospitalization</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Chronic Heart Failure</condition>
  <condition>Preserved Ejection Fraction</condition>
  <arm_group>
    <arm_group_label>Patients with chronic HF with preserved ejection fraction coming for scheduled day hospitalization</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clinical examination focusing on congestion&#xD;
Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds&#xD;
Blood sample retrieved for biological assessment and biobanking&#xD;
Telephone follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Clinical examination centered on congestion</intervention_name>
    <description>Clinical examination centered on congestion (including the EVEREST score) will be performed during day hospitalization</description>
    <arm_group_label>Patients with chronic HF with preserved ejection fraction coming for scheduled day hospitalization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds</intervention_name>
    <description>Cardiac, pulmonary, peritoneal, jugular and renal venous Doppler ultrasounds will be performed during day hospitalization/ peritoneal, jugular and renal venous Doppler ultrasounds are optional</description>
    <arm_group_label>Patients with chronic HF with preserved ejection fraction coming for scheduled day hospitalization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Blood sample retrieved for biological assessment and biobanking</intervention_name>
    <description>Blood sample retrieved for biological assessment and biobanking will be performed during day hospitalization</description>
    <arm_group_label>Patients with chronic HF with preserved ejection fraction coming for scheduled day hospitalization</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Telephone follow-up</intervention_name>
    <description>Telephone follow-up will be performed 3, 12 and 24</description>
    <arm_group_label>Patients with chronic HF with preserved ejection fraction coming for scheduled day hospitalization</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with chronic acute heart failure with preserved ejection fraction admitted in&#xD;
             hospital for scheduled day hospitalization&#xD;
&#xD;
          -  Patient with preserved left ventricular ejection fraction (≥50%).&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  Patients having received complete information regarding the study design and having&#xD;
             signed their informed consent form.&#xD;
&#xD;
          -  Patient affiliated to or beneficiary of a social security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Comorbidity for which the life expectancy is ≤ 3 months&#xD;
&#xD;
          -  Dialysis patient (peritoneal dialysis or hemodialysis) or patients with glomerular&#xD;
             filtration rate &lt;15 ml/min/m2 at inclusion.&#xD;
&#xD;
          -  History of lobectomy or pneumonectomy lung surgery&#xD;
&#xD;
          -  Severe pulmonary or pleural pathology preventing reliable acquisition of lung&#xD;
             ultrasound images: severe emphysema, chronic pleurisy, pulmonary fibrosis, etc.&#xD;
&#xD;
          -  Pregnant woman, parturient or nursing mother&#xD;
&#xD;
          -  Adult person subject to a legal protection measure (guardianship, curatorship,&#xD;
             safeguard of justice)&#xD;
&#xD;
          -  Adult person who is unable to give consent&#xD;
&#xD;
          -  Person deprived of liberty by a judicial or administrative decision,&#xD;
&#xD;
          -  Person subject to psychiatric care pursuant to Articles L. 3212-1 and L. 3213-1 of the&#xD;
             Public Health Code.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Nicolas GIRERD, MD, PhD</last_name>
    <phone>+ 33 3 83 15 73 22</phone>
    <phone_ext>+ 33 3</phone_ext>
    <email>n.girerd@chru-nancy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sanae BOUALI</last_name>
    <phone>+ 33 3 83 15 73 22</phone>
    <phone_ext>+ 33 3</phone_ext>
    <email>s.bouali@chru-nancy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>CHRU de Nancy</name>
      <address>
        <city>Vandoeuvre Les Nancy</city>
        <zip>54500</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Nicolas GIRERD, MD, PhD</last_name>
      <phone>+33383157322</phone>
      <phone_ext>+333</phone_ext>
      <email>n.girerd@chru-nancy.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 11, 2021</study_first_submitted>
  <study_first_submitted_qc>October 27, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2021</study_first_posted>
  <last_update_submitted>October 27, 2021</last_update_submitted>
  <last_update_submitted_qc>October 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Central Hospital, Nancy, France</investigator_affiliation>
    <investigator_full_name>Pr. Nicolas GIRERD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

